PIONEER-HF was a multicenter, randomized, double-blind, double dummy, parallel group, active-controlled 8-week study to evaluate the effect of sacubitril and valsartan (LCZ696) versus enalapril on changes in NT-proBNP and safety and tolerability of in-hospital initiation of LCZ696 compared to enalapril in HFrEF patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF).
MAIN RESULTS:
Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure

PRESENTATIONS
Safety and Efficacy of Sacubitril/Valsartan by Dose Level in Patients Hospitalized with Acute Heart Failure (Morrow, ESC 2019)
PIONEER High-risk Subgroups (Berg, AHA 2019)